GWPH - Better Buy: GW Pharmaceuticals vs. Cara Therapeutics
GW Pharmaceuticals (NASDAQ: GWPH) and Cara Therapeutics (NASDAQ: CARA) often get lumped together as cannabinoid-focused biotechs. However, that label is really only applicable to GW Pharmaceuticals. Although Cara Therapeutics has done some preclinical testing on a cannabinoid receptor agonist and holds some patents on cannabinoid compounds, the company doesn't really focus on cannabinoid development.
So far in 2020, GW has been the bigger winner, gaining 16% compared to Cara's single-digit-percentage increase. But which of these two biotech stocks is the better pick over the long run?
Image source: Getty Images.